Skip to main content

Table 2 Characteristics of patients with respect to prior daptomycin exposure

From: Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus

  Prior Daptomycin Exposure No Daptomycin Exposure P value*
Number of Isolates 15 (60%) 10 (40%) --
Age 52.5 51.8 --
Sex – no (%)    
-Female 8/15 (53%) 6/10 (60%) 0.742
Isolate    
-E. faecium 14 (93%) 4 (67%) 0.115
-E. faecalis 0 (0%) 2 (33%) 0.019
-Species Not Identified 1 (7%) 0 (0%) --
-Isolate Not Availablea 0 4 --
Source    
-Bloodb 7 (47%) 2 (20%) 0.174
-Urineb 5 (33%) 7 (70%) 0.072
-Peritoneal Fluid 2 (13%) 1 (10%) 0.802
-Wound 2 (13%) 0 (0%) 0.229
-Colonizationc 4 (27%) 4 (40%) 0.484
Past Medical History    
-Diabetes 6 (40%) 6 (60%) 0.327
-ESRD/Dialysis 2 (13%) 1 (10%) 0.802
-Cancer/Chemotherapyd 8 (53%) 4 (40%) 0.513
-History of Transplant 2 (13%) 0 (0%) 0.229
-CVDe 3 (20%) 4 (40%) 0.275
-Lung Diseasef 2 (13%) 2 (20%) 0.656
GI or Intra-abdominal Processg 12 (80%) 7 (70%) 0.566
Immunosuppressionh 14 (93%) 7 (70%) 0.119
Deathi 8 (53%) 2 (20%) 0.096
  1. Note:
  2. * - All P values were calculated with the use of the chi-square test.
  3. a – Four isolates were not available for species identification.
  4. b – One patient with DNSE and prior daptomycin exposure had DNSE isolated from both blood and urine.
  5. c – All colonizing isolates were obtained from urine of patients without symptoms and/or negative urinalysis.
  6. d – includes all patients with acute lymphoblastic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, bone marrow transplant, stem cell transplant, solid organ tumor, and those undergoing chemotherapy.
  7. e – includes all patients with coronary artery disease, congestive heart failure, cerebro-vascular accident, peripheral vascular disease, and valvular heart disease.
  8. f – includes all patients with chronic obstructive pulmonary disease and pulmonary hypertension.
  9. g – includes all patients with Clostridium difficile infection, graft-versus-host-disease of the gut, neutropenic enterocolitis/perforation, traumatic bowel perforation, bowel ischemia, bacterial peritonitis, ascending cholangitis, gastroparesis, pyelonephritis and/or kidney abscess, or other gastrointestinal surgery with complications.
  10. h – includes all patients with any cancer or undergoing chemotherapy, diabetes mellitus, ESRD/HD, organ transplant.
  11. i – Hospital and/or thirty-day mortality from any cause.